Sugi Predict

Sugi Predict / Compounds / SCHEMBL3829101

SCHEMBL3829101

SCHEMBL3829101

Nc1nc(C(=O)c2ccccc2)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.50
▸ ALDH1A1 P00352 9/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ KDM4B O94953 2/20 0.46
▸ KDM5C P41229 2/20 0.46
▸ KDM5B Q9UGL1 2/20 0.46
▸ KDM6B O15054 1/20 0.46
▸ KDM4A O75164 1/20 0.46
▸ KDM2A Q9Y2K7 1/20 0.46
▸ KDM3A Q9Y4C1 1/20 0.46
▸ MEN1 O00255 5/20 0.46
▸ LMNA P02545 3/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ USP2 O75604 1/20 0.46
▸ GLA P06280 1/20 0.46
▸ CNR2 P34972 1/20 0.46
▸ MAPT P10636 5/20 0.45
▸ NPC1 O15118 4/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ CA2 P00918 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27594585 0.98 KMT2A (0.49) KMT2AALDH1A1KDM4EKDM4BKDM5C
SCHEMBL9047705 0.86 ALDH1A1 (0.47) KMT2AALDH1A1KDM4EKDM4BKDM5C
SCHEMBL27183783 0.83 MAPT (0.49) KMT2AALDH1A1KDM4EMEN1LMNA
SCHEMBL27662308 0.82 ALDH1A1 (0.55) KMT2AALDH1A1KDM4EKDM4BKDM5C
SCHEMBL1669181 0.80 KMT2A (0.52) KMT2AALDH1A1MEN1LMNAHSD17B10
SCHEMBL4455537 0.80 KMT2A (0.52) KMT2AALDH1A1MEN1LMNAHSD17B10
SCHEMBL6189533 0.79 HDAC1 (0.43) KMT2AALDH1A1KDM4EHSD17B10CNR2
SCHEMBL4455543 0.79 KMT2A (0.50) KMT2AALDH1A1MEN1LMNAHSD17B10
SCHEMBL13475954 0.79 TLR7 (0.53) KMT2AALDH1A1KDM4EKDM4BKDM5C
SCHEMBL4331781 0.78 ALDH1A1 (0.73) KMT2AALDH1A1KDM4EKDM4BKDM5C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11427575-B2 Antitumor compound for activating JWA gene and degrading HER2, preparation method thereof, and application thereof SIMCERE PHARMACEUTICAL CO., LTD. (CN) 2022-08-30 — — US claimed
EP-1694673-B1 THIAZOLE DERIVATES HOFFMANN LA ROCHE (CH) 2008-01-16 — — EP claimed
JP-2007513193-A — — 2007-05-24 — — JP claimed
EP-1694673-A1 NOVEL THIAZOLE DERIVATES F.HOFFMANN-LA ROCHE AG (CH) 2006-08-30 — — EP claimed
US-20050153962-A1 Thiazole derivatives HOFFMANN-LA ROCHE INC. 2005-07-14 — — US claimed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 — — WO claimed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 — — US disclosed
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 — — US disclosed
US-11427575-B2 Antitumor compound for activating JWA gene and degrading HER2, preparation method thereof, and application thereof SIMCERE PHARMACEUTICAL CO., LTD. (CN) 2022-08-30 — — US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 — — US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 — — US disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 — — WO disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 — — WO disclosed
WO-2005058887-A1 NOVEL THIAZOLE DERIVATES F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 — — WO disclosed
US-20050143581-A1 Process for preparation of alkoxybenzamides and thiazolyl isocyanates MITSUI CHEMICALS, INC. (JP) 2005-06-30 — — US disclosed
EP-1529530-A1 Compounds affecting glucokinase AstraZeneca AB (SE) 2005-05-11 — — EP disclosed
CN-1568185-A Compounds affecting glucokinase ASTRAZENECA AB (SE) 2005-01-19 — — CN disclosed
EP-1489073-A1 PROCESS FORPREPARATION OF ALKOXYBENZAMIDES AND THIAZOLYL ISOCYANATES MITSUI CHEMICALS, INC. (JP) 2004-12-22 — — EP disclosed
CN-1084739-C Process for producing 2-hydroxybenzamide derivatives ZERIA PHARMACEUTICAL CO.,LTD. (JP) 2002-05-15 — — CN disclosed
CN-1261357-A Process for preparing 2-hydroxybenzamide derivatives ZERIA PHARM CO LTD (JP) 2000-07-26 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 KMT2A 805/4885ALDH1A1 2267/4885KDM4E 1848/4885
US-20050143581-A1 Process for preparation of alkoxybenzamides and thiazolyl isocyanates CBR3, CBR1, IDH1 KMT2A 613/4885ALDH1A1 65/4885KDM4E 616/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 KMT2A 805/4885ALDH1A1 2267/4885KDM4E 1848/4885
US-20050153962-A1 Thiazole derivatives CNR1, CNR2, GPR119 KMT2A 3489/4885ALDH1A1 473/4885KDM4E 3200/4885
US-11427575-B2 Antitumor compound for activating JWA gene and degrading HER2, preparation method thereof, and application thereof EGFR, ERBB2, ERBB3 KMT2A 152/4885ALDH1A1 1994/4885KDM4E 2679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.